Coreline's 'Brain Hemorrhage Diagnosis Support AI' Supplied to Gangbuk Samsung Hospital

Coreline Soft announced on the 23rd that it has supplied its AI-based intracerebral hemorrhage diagnosis solution, AVIEW NeuroCAD, to Gangbuk Samsung Hospital. This is the first time AVIEW NeuroCAD has been supplied to a tertiary general hospital. Currently, when combined with other AVIEW product lines, 30 out of 47 tertiary general hospitals have adopted AVIEW, accounting for 70%, the company explained.

AVIEW NeuroCAD, an AI-assisted intracerebral hemorrhage diagnosis solution, utilizes deep learning technology to detect intracerebral hemorrhage from computed tomography (CT) images and assist diagnosis. It has been designated as an innovative medical device in recognition of its technological innovation. The solution features prioritization of severe patients with heavy bleeding, 2D and 3D viewers to check the amount and distribution of hemorrhage, and emergency patient message alerts, helping medical staff respond proactively. It also integrates with medical institutions' Picture Archiving and Communication Systems (PACS), improving workflow efficiency in emergency settings. Since entering the non-reimbursed and selective reimbursement market in January, 16 hospitals including Inje University Ilsan Paik Hospital, Gumi CHA Hospital, and Sejong Chungnam National University Hospital have adopted the product.

Earlier this year, Coreline Soft also supplied its chest disease diagnosis solution, AVIEW LCS Plus, to Gangbuk Samsung Hospital, continuously introducing the latest imaging diagnostic equipment and pursuing strategic collaboration.

Kim Jin-guk, CEO of Coreline Soft, stated, “We will reaffirm our pivotal role in the emergency medical field, where the importance of AI is increasingly emphasized, through innovative technologies and products. Beyond product adoption, we will provide AI education programs and consulting to promote continuous collaboration and development.”